Health Condition 1: F339- Major depressive disorder, recurrent, unspecified
Conditions
Interventions
Intervention1: vortioxetine and Escitalopram: oral route of administration
dosage vortioxetine 10mg,escitalopram 5mg
frequency at 2nd,4th,8th and 12th week
Control Intervention1: vortioxetine with esc
Sponsors
nil
Eligibility
Inclusion criteria
Inclusion criteria: 1)Adult Patients (18-65 years old) diagnosed with MDD based on DSM-5 criteria. 2) Patients Presenting to the tertiary Care Hospital outpatient Department with moderate to severe symptoms. 3) Willingness to Provide informed consent for participation in the study.
Exclusion criteria
Exclusion criteria: •Patients with a history of bipolar disorder, psychotic disorder, or substance abuse within the past six months. •Concurrent use of other antidepressants or psychotropic medications. •Patients with previous depression resistant to antidepressants and those who had taken treatment with ECT in previous 3 months or formal psychotherapy within 1 month. •Pregnancy or lactation. •Patients with drug intake for psychosis or anxiety. •Any history of allergy to the drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The Proportion of Participants achieving HAM D score of 7 at 12 weeks with vortioxetine vs escitalopramTimepoint: Till 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1 To assess the safety & tolerability profiles of vortioxetine & escitalopram. 2 To explore any demographic or clinical factors that may influence treatment response. Timepoint: till 12 weeks | — |
Countries
India
Contacts
Public ContactDr Vinod Shivajirao Deshmukh
Vilasrao Deshmukh Government Medical College
Outcome results
None listed